A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.

Slides:



Advertisements
Similar presentations
Professional Education Support Wyeth Pharmaceuticals Melinda Somasekhar, PhD.
Advertisements

CME 101 The Application Process Sponsored by the Office of Continuing Medical Education.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
Hot Topics Commercial Support. What is Commercial Support? Commercial Support is financial or in- kind contributions given by a commercial interest which.
Commercial support is defined as financial or in- kind contributions given by a commercial interest, which is used to pay all or part of the costs of a.
Reinventing Medical Education Marissa Seligman, PharmD VP & Compliance Officer Pri-Med Institute, Boston, MA June 7, 2005.
15th Annual Primary Care Update May 8-12, 2012
Consulting Services Our core consulting services focus on government and commercial health programs from both sides: our provider-physicians and health.
A REVIEW FOR ALL PRESENTERS OF ASMBS-SPONSORED EDUCATIONAL ACTIVITIES ASMBS CME Policies, Procedures and Guidelines for Presenters.
Internal Auditing and Outsourcing
Clinical Compliance Programs: Investigator Payments, GCPs, and More…. Teri Crouse, J.D. Director of Compliance for Healthcare & Marketing.
Exploring the Accreditation Criterion 1-15 BEST PRACTICES.
August, 2005 Slide 1 MANAGING RISKS OF OFF-LABEL PROMOTION AND CONTINUING MEDICAL EDUCATION The FDA Regulatory and Compliance Symposium Annenberg Hall.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Standards for Commercial Support: Standards to Ensure Independence in CME Activities SM Case Studies.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
The Medical Device Regulatory and Compliance Congress
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
(Name of Conference) Housekeeping Slides Welcome to the Name of Conference These are our daily announcements.
Jointly Sponsored by The Warren Alpert Medical School of Brown University and the New England Regional Chapter of the Society of Adolescent Health and.
+ Conflict of Interest in Physician-Industry Relationships.
ACCREDITATION CRITERIA CONFLICT OF INTEREST CONTENT INTEGRITY.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
Disclosure of Financial Conflicts of Interest in Continuing Medical Education Michael D. Jibson, MD, PhD and Jennifer Seibert, MD University of Michigan.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
+ Role of Industry in Clinical Care, Research, and Education.
Continuing Medical Education
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
NJE rnicHR1 This report is solely for the use of client personnel. No part of it may be circulated, quoted, or reproduced for distribution.
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Special Program for Internal/Compliance Audit Professionals: Enterprise Risk.
Agenda for Session Compliance in Clinical Research
Sara Lovell, CPCS Education Coordinator Providence Alaska Medical Center.
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
Distance Learning and Accreditation Heather G. Hartman, Ph.D. Brenau University Online Studies and SACS Liaison.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
ACCME at the International Pharmaceutical Compliance Summit Philadelphia March 2005.
Company: Cincinnati Insurance Company Position: IT Governance Risk & Compliance Service Manager Location: Fairfield, OH About the Company : The Cincinnati.
Jointly Sponsored by The Warren Alpert Medical School of Brown University and the New England Regional Chapter of the Society of Adolescent Health and.
California’s New Compliance Law Kelly N. Reeves
Speaker Disclosure Explanation
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
Title of Presentation Speaker Names, Credentials, Full Title Collaborative Family Healthcare Association 13 th Annual Conference October 27-29, 2011 Philadelphia,
1 Compliance vs. the Law Department: How to Work Together Michael Dusseau Senior Director, Compliance North America Schering-Plough David Ralston, Esq.
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.
Department of Computer Science Introduction to Information Security Chapter 8 ISO/IEC Semester 1.
CME Process and Accreditation Criteria Objectives Explain Updated ACCME Accreditation Criteria Utilize the revised CME Planning Process to incorporate.
Continuing Medical Education Guidance for Planners of Regularly Scheduled Series (RSS) To insert your company logo on this slide From the Insert Menu Select.
PUBLICATION PRINCIPLES for PUBLICATION PROFESSIONALS
The IVD Australia Code of Conduct Edition 2.1
Neurological Clinicopathologic Case Presentation
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
Contemporary Paradigms for Anticoagulant Reversal
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
Conflict of Interest Disclosure
CME and Consultants Compliance Roundtable
Lilly Grant Funding Disclosure May 27, 2008
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Industry Induction Course
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
ASMBS CME Policies, Procedures and Guidelines for Presenters
Presentation transcript:

A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal for Life Sciences and Healthcare Deloitte Consulting

Disclaimer The information presented represents the opinions of the authors and does not necessarily reflect the views of AstraZeneca Pharmaceuticals LP or Deloitte & Touche LLP

Topics Discussed Review of business practices that can create off-label risk Standards and guidelines governing CME and grants Factors to consider in risk management of CME and grants

Business Practices That Can Create Off-Label Risk Sales representative activities Field medical activities Reprint use Third party relationships Pharmacy benefit manager/GPO interactions Use of Consultants

Business Practices That Can Create Off-Label Risk (continued) Use of Speakers Clinical research grants Publications Sampling Activity Continuing Medical Education

CME Conundrum Physicians are required to earn CME credits to maintain their certification *In 2003, over half of the funding for CME programs was derived from commercial support Result: increased scrutiny of CME events…but also increased guidance to improve quality * Murray Kopelow, ACCME at the International Pharmaceutical Compliance Summit, Philadelphia, March 2005

Quotes from Neurontin Case Coverage “The Justice Department said in its filing backing the whistle-blower that a medical education program sponsored by Parke-Davis ‘was actually a massive promotion of Neurontin for pain.’” The Pharmaceutical Corporate Compliance Report 9/2/03

Standards for CME and grants FDA Guidance on Industry-Supported Scientific and Educational Activities ACCME Standards for Commercial Support PhRMA Code on Interactions with Healthcare Professionals OIG Compliance Program Guidance for Pharmaceutical Manufacturers

FDA Guidance on Industry-Supported Scientific And Educational Activities FDA does not regulate as labeling and advertising independent scientific and educational events or enduring materials funded by industry FDA published 12 factors to be used in evaluating program independence

FDA 12 Factors Control of Content and Selection of Presenters and Moderators Disclosures Focus of the Program Relationship between the Provider and the Company Provider Involvement in Sales or Marketing Provider’s Demonstrated Failure to Meet Standards

FDA 12 Factors Multiple Presentations Audience Selection Opportunities for Discussion Dissemination Ancillary Promotional Activities Complaints

ACCME Standards for Commercial Support Standard 1: Independence Standard 2: Resolution of Personal Conflicts of Interest Standard 3: Appropriate Use of Commercial Support Standard 4: Appropriate Management of Associated Commercial Promotion

ACCME Standards for Commercial Support, (cont.) Standard 5: Content and Format without Commercial Bias Standard 6: Disclosures Relevant to Potential Commercial Bias

PhRMA Code Third-Party Educational or Professional Meetings Acceptable for companies to support educational/scientific events Financial support for travel,lodging or time spent at conference for attendees (I.e., not presenters) may not be offered Modest meals and receptions may be provided either through the grant or may be directly provided according to the sponsoring organizations guidelines

OIG Guidance Educational grants May be appropriate for companies to fund Anti-kickback concerns Inappropriate marketing concerns Independence concerns

OIG Guidance/California law Considerations for decreasing risk Separate decisions for grant funding from Sales and Marketing Establish clear criteria for funding tied to educational objectives – not to increased sales No control over speakers or content of program Document and monitor!

Factors to Consider in Risk Management Changes in processes and procedures for Company Accrediting providers Vendors

Company decisions Do we want to continue our commitment to healthcare provider independent education? If yes, what policies/SOPs should be changed to ensure lack of company influence on educational program? Where and how will documentation of review and approval be housed?

Company decisions What is our definition of “separation of the grant making functions from Sales and Marketing”? How are we going to monitor adherence to our SOPs and policies for CME and educational grants? What is an appropriate governance model for a company for management of CME and educational grants?

Accrediting provider decisions Are we willing to expend more energy than in the past to create a robust proposal (with needs assessments, learning objectives, etc.) to submit for company funding? Are we willing to create and implement a rigorous Conflict of Interest process?

Accrediting provider decisions Are we willing to evaluate the effectiveness of the learning for our programs and our MedEd/MedComm partners?

Vendor decisions Are we willing to create a firewall or even separate companies for promotional programs vs. independent education? Are we willing to cut our ties with the Marketing arms of companies when designing independent educational programs?

Vendor decisions Are we willing to create bona fide and robust needs assessments for programs for which we are seeking company support? Are we willing to work with a more diverse set of thought leaders as we plan educational events?

Summary There has been concern among government agencies and accrediting providers that independent education programs may be used inappropriately for the dissemination of marketing messages A number of guidances and standards have been released recently to ensure that CME and other independent educational programs are free from company influence

Summary Adherence to new guidelines and standards requires behavior changes on the part of all involved with independent education